Stocks & Investing
Stocks and Investing
Stocks and Investing
Sun, September 27, 2009
Fri, September 25, 2009
Thu, September 24, 2009 OraSure Technologies (OSUR) Daily Short Sale Trading Volume Through 9-23-09
September 24, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NYSE, NASDAQ, BX, CHX and NSX Daily Short Volume Report through Wednesday, September 23rd, 2009 and come to the following statistical conclusions. The chart below shows aggregated daily short volume in OraSure Technologies (NASDAQ: OSUR) for August through September 23, 2009. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.
Date Short Volume Total Volume Percent
9/23/2009 7,340 177,187 4.14%
9/22/2009 37,402 328,700 11.38%
9/21/2009 27,744 204,500 13.57%
9/18/2009 108,466 252,300 42.99%
9/17/2009 17,950 97,400 18.43%
9/16/2009 17,006 75,500 22.52%
9/15/2009 2,900 41,000 7.07%
9/14/2009 14,014 129,700 10.80%
9/11/2009 17,160 131,900 13.01%
9/10/2009 29,425 295,600 9.95%
9/9/2009 16,645 337,700 4.93%
9/8/2009 12,462 158,400 7.87%
9/4/2009 19,374 128,700 15.05%
9/3/2009 1,300 70,100 1.85%
9/2/2009 8,133 107,400 7.57%
9/1/2009 8,362 109,300 7.65%
8/31/2009 5,108 150,741 3.39%
8/28/2009 11,360 131,900 8.61%
8/27/2009 20,625 134,600 15.32%
8/26/2009 48,355 369,200 13.10%
8/25/2009 8,671 340,700 2.55%
8/24/2009 28,561 217,800 13.11%
8/21/2009 74,049 199,800 37.06%
8/20/2009 20,003 172,900 11.57%
8/19/2009 6,957 147,900 4.70%
8/18/2009 9,282 75,800 12.25%
8/17/2009 39,900 133,500 29.89%
8/14/2009 17,025 199,600 8.53%
8/13/2009 8,567 120,500 7.11%
8/12/2009 7,189 288,000 2.50%
8/11/2009 17,583 168,200 10.45%
8/10/2009 11,469 95,300 12.03%
8/7/2009 20,114 156,400 12.86%
8/6/2009 14,545 126,800 11.47%
8/5/2009 13,350 130,500 10.23%
8/4/2009 5,500 49,500 11.11%
8/3/2009 6,785 54,300 12.50%
Total 740,681 6,109,328 12.12%
In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.
Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.
The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.
OraSure Technologies, Inc. (NASDAQ: OSUR) engages in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types, and other medical devices. The companya�s diagnostic products include tests which are performed on a rapid basis at the point of care and tests which are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physiciansa� offices, and commercial and industrial entities. Products OraQuick Rapid Test Platform OraQuick is the companya�s rapid test platform designed to test oral fluid, whole blood (both finger-stick and venous), plasma and serum samples for the presence of various antibodies or analytes. The device uses a porous flat pad to collect an oral fluid specimen. The company has commercialized this technology in the form of its OraQuick ADVANCE rapid HIV-1/2 antibody test. This is a rapid, point-of-care test for the detection of antibodies to both HIV-1 and HIV-2 in oral fluid, finger-stick and venous whole blood and plasma. The company has also received a Clinical Laboratory Improvements Amendment of 1988 (CLIA) waiver for use of the OraQuick ADVANCE test with oral fluid and finger-stick and venous whole blood. The company obtained a CE mark for its OraQuick ADVANCE test so that it can sell this product in Europe and other countries accepting the CE mark for commercialization. It has distributors in place for the United Kingdom, Ireland, Spain, Russia and France and is pursuing distribution arrangements in various additional European countries. The company is selling the OraQuick HIV-1/2 test in Mexico and Africa and is completing registrations in various countries in Latin America, Asia and the Middle East. OraSure/Intercept Collection Devices The companya�s OraSure oral fluid collection device is used in conjunction with screening and confirmatory tests for HIV-1 antibodies and other analytes. This device consists of a small, treated cotton-fiber pad on a handle that is placed in a persona�s mouth for two to five minutes. The device collects oral mucosal transudate (OMT), a serum-derived fluid that contains higher concentrations of certain antibodies and analytes than saliva. The company markets the OraSure oral fluid collection device for use in screening life insurance applicants in the United States and internationally to test for three underwriting risk factors: HIV-1, cocaine and cotinine (a metabolite of nicotine). Devices are sold to insurance testing laboratories, including Quest Diagnostics, Heritage Labs and Clinical Reference Laboratory. The company received a CE mark for the Intercept and OraSure devices and its oral fluid assays, all of which are distributed in Canada, the United Kingdom and Mexico. The OraSure device and the companya�s oral fluid drugs of abuse assays are also sold in various other foreign countries. Cryosurgical Systems (Skin Lesion Removal Products) The company has received 510(k) clearance to market and sell a cryosurgical product similar to the Histofreezer product in the OTC or retail market for the removal of common and plantar warts only. In early 2009, the company launched its OTC cryosurgical wart product in the U.S. under a new national brand called Freeze an Clear Skin Clinic. Internationally, the company distributes a CE marked cryosurgical wart removal product into the OTC footcare market in Europe, Australia and New Zealand through its distributor, SSL International plc (SSL), under the Scholl and Dr. Scholl trademarks. SSL is the owner of the Scholl and Dr. Scholl trademarks in countries outside North and South America. It also distributes an OTC cryosurgical product through its distributor Genomma Labs, under the POINTTS tradename, in Mexico, a number of South and Central American countries, and South Africa. Immunoassay Tests and Reagents The company develops and sells immunoassay tests in two formats, known as MICRO-PLATE and AUTO-LYTE, to meet the specific needs of its customers. MICRO-PLATE tests can be performed on commonly used instruments and can detect drugs in urine, serum and sweat specimens. MICRO-PLATE tests are also used as part of the Intercept product line to detect drugs of abuse in oral fluid specimens. AUTO-LYTE tests are sold in the form of bottles of liquid reagents. These reagents are run on commercially available laboratory-based automated analytical instruments, which are manufactured by various third parties. AUTO-LYTE is typically used in high volume, automated, commercial reference insurance laboratories to detect certain drugs or chemicals in urine. Western blot HIV-1 Confirmatory Test The company sells an oral fluid Western blot HIV-1 confirmatory test. This test uses the original specimen collected with the OraSure oral fluid collection device to confirm positive results of initial oral fluid HIV-1 EIA screening tests. Q.E.D. Saliva Alcohol Test The companya�s Q.E.D. saliva alcohol test is a point-of-care test device that is an alternative to breath or blood alcohol testing. Each Q.E.D. test kit contains a collection stick that is used to collect a sample of saliva and a disposable detection device that displays results in a format similar to a thermometer. The product has a testing range of 0 to 0.145% blood alcohol and produces results in approximately two minutes. Products under Development OraQuick Platform OraQuick provides a platform technology that can be modified for detection of a variety of infectious diseases in addition to HIV, such as viral hepatitis and certain sexually transmitted diseases. It is devoting significant resources to obtaining FDA approval to sell its OraQuick HIV-1/2 test in the United States OTC market. The company has completed an observed user study and submitted its data to the FDA. The company obtained rights to a HCV test manufactured by a third party for distribution into certain developing foreign countries. The company has agreements with Schering-Plough Corporation (Schering-Plough) to collaborate on the development and promotion of its OraQuick HCV test for use with oral fluid. OraSure/Intercept Applications OraSure and Intercept devices are a platform technology with a range of applications, where laboratory testing is available. The OraSure device may be useful for the collection of various antibodies or markers for infectious diseases or conditions in addition to HIV-1, such as antibodies to viral hepatitis. The company is developing modifications to the Intercept collection device. It is developing additional drugs of abuse assays for use with its Intercept collection device. In 2008, the company signed a development agreement with Roche Diagnostics for homogeneous fully-automated oral fluid drugs of abuse assays that can be run on random access chemistry analyzers. OTC Cryosurgical Systems Products The company sells its Histofreezer cryosurgical systems product in the physiciansa� office or professional market. Its OTC cryosurgical product has been approved by the FDA for two types of skin lesions a" common warts and plantar warts. The company submitted an application for FDA 510(k) clearance of an OTC cryosurgical product for one of these indications and that application remains pending before the FDA. Markets The company markets its products to physiciansa� offices, insurance risk assessment, substance abuse, public health and laboratory testing in the United States and Canada. It markets cryosurgical wart removal products in the OTC footcare market in Europe, Australia and New Zealand. Customers During 2008, the companya�s customers included Quest Diagnostics, Incorporated and Abbott Laboratories. Competition The companya�s competitors include Johnson & Johnson, Bio-Rad Laboratories, Abbott, Maxim Biomedical MedMira, Trinity Biotech, Inverness Medical/Chembio, Ansys Technologies, Inc., Dade Behring, Psychemedics, Immunalysis, Roche Diagnostics, Microgenics, Inc., Immunalysis, Cryosurgery, Inc., Wartner, Schering-Plough, Ansys Technologies, Inc., Chematics, Intoximeters , Drager and CMI. History OraSure Technologies, Inc. was founded in 1979.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net
